Royalty Pharma Posts $145M Third-Quarter Net Income
RPRX sits 85% above its 52-week low of $36.027.
Summary
Royalty Pharma reported third-quarter net income of $145 million on revenue of $690 million. The headline gives only the bottom line, with no portfolio receipts, guidance update, or comparison to prior periods, so the quality of the quarter is not yet clear. Context matters here: Q2 portfolio receipts came in at $773 million, up 6% year-over-year, and management raised full-year guidance to $3.4–$3.5 billion, so the bar for Q3 was set high. The stock is trading near its 52-week high, which leaves little room for a soft quarter. Watch the full release for portfolio receipts versus the raised guidance range and any update to the $3.4–$3.5 billion full-year outlook. For 2026, the company sees portfolio receipts of $3.5 billion to $3.55 billion.
At the time of this announcement, RPRX was trading at $66.58 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $38.3B. The 52-week trading range was $36.03 to $67.71. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.